Veraxa Biotech AG - Post de-SPAC(VRXA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings.

Veraxa Biotech AG - Post de-SPAC (VRXA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. VRXA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of VRXA by reported 13-F value include UBS Group AG, GEODE CAPITAL MANAGEMENT, CSS, based on the most recent SEC filings. VRXA trades on the Nasdaq exchange and files with the SEC under CIK 2079109. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRXA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Veraxa Biotech AG - Post de-SPAC directly from SEC EDGAR.